Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 321

1.

Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease.

Huotarinen A, Penttinen AM, Bäck S, Voutilainen MH, Julku U, Piepponen TP, Männistö PT, Saarma M, Tuominen R, Laakso A, Airavaara M.

Neuroscience. 2018 Mar 15;374:250-263. doi: 10.1016/j.neuroscience.2018.01.052. Epub 2018 Feb 3.

2.

Copy number elevation of 22q11.2 genes arrests the developmental maturation of working memory capacity and adult hippocampal neurogenesis.

Boku S, Izumi T, Abe S, Takahashi T, Nishi A, Nomaru H, Naka Y, Kang G, Nagashima M, Hishimoto A, Enomoto S, Duran-Torres G, Tanigaki K, Zhang J, Ye K, Kato S, Männistö PT, Kobayashi K, Hiroi N.

Mol Psychiatry. 2018 Apr;23(4):985-992. doi: 10.1038/mp.2017.158. Epub 2017 Aug 22.

3.

Delayed O-methylation of l-DOPA in MB-COMT-deficient mice after oral administration of l-DOPA and carbidopa.

Tammimäki A, Aonurm-Helm A, Männistö PT.

Xenobiotica. 2018 Apr;48(4):325-331. doi: 10.1080/00498254.2017.1315781. Epub 2017 Apr 21.

PMID:
28375049
4.

Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.

Voutilainen MH, De Lorenzo F, Stepanova P, Bäck S, Yu LY, Lindholm P, Pörsti E, Saarma M, Männistö PT, Tuominen RK.

eNeuro. 2017 Mar 13;4(1). pii: ENEURO.0117-16.2017. doi: 10.1523/ENEURO.0117-16.2017. eCollection 2017 Jan-Feb.

5.

Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?

Männistö PT, García-Horsman JA.

Front Aging Neurosci. 2017 Feb 14;9:27. doi: 10.3389/fnagi.2017.00027. eCollection 2017.

6.

Generation of membrane-bound catechol-O-methyl transferase deficient mice with disctinct sex dependent behavioral phenotype.

Tammimaki A, Aonurm-Helm A, Zhang FP, Poutanen M, Duran-Torres G, Garcia-Horsman A, Mannisto PT.

J Physiol Pharmacol. 2016 Dec;67(6):827-842.

7.
8.

Deficiency of prolyl oligopeptidase in mice disturbs synaptic plasticity and reduces anxiety-like behaviour, body weight, and brain volume.

Höfling C, Kulesskaya N, Jaako K, Peltonen I, Männistö PT, Nurmi A, Vartiainen N, Morawski M, Zharkovsky A, Võikar V, Roßner S, García-Horsman JA.

Eur Neuropsychopharmacol. 2016 Jun;26(6):1048-61. doi: 10.1016/j.euroneuro.2016.02.015. Epub 2016 Feb 27.

PMID:
26996375
9.

COMT gene locus: new functional variants.

Meloto CB, Segall SK, Smith S, Parisien M, Shabalina SA, Rizzatti-Barbosa CM, Gauthier J, Tsao D, Convertino M, Piltonen MH, Slade GD, Fillingim RB, Greenspan JD, Ohrbach R, Knott C, Maixner W, Zaykin D, Dokholyan NV, Reenilä I, Männistö PT, Diatchenko L.

Pain. 2015 Oct;156(10):2072-83. doi: 10.1097/j.pain.0000000000000273.

10.

Epistasis between polymorphisms in COMT, ESR1, and GCH1 influences COMT enzyme activity and pain.

Smith SB, Reenilä I, Männistö PT, Slade GD, Maixner W, Diatchenko L, Nackley AG.

Pain. 2014 Nov;155(11):2390-9. doi: 10.1016/j.pain.2014.09.009. Epub 2014 Sep 16.

11.

Synthesis and biological evaluation of novel (123)I-labeled 4-(4-iodophenyl)butanoyl-L-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo.

Kallinen A, Todorov B, Kallionpää R, Bäck S, Sarparanta M, Raki M, García-Horsman JA, Bergström KA, Wallén EA, Männistö PT, Airaksinen AJ.

Eur J Med Chem. 2014 May 22;79:436-45. doi: 10.1016/j.ejmech.2014.04.014. Epub 2014 Apr 12.

PMID:
24763264
12.

The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Savolainen MH, Richie CT, Harvey BK, Männistö PT, Maguire-Zeiss KA, Myöhänen TT.

Neurobiol Dis. 2014 Aug;68:1-15. doi: 10.1016/j.nbd.2014.04.003. Epub 2014 Apr 16.

PMID:
24746855
13.

High correlation between in vivo [123I]β-CIT SPECT/CT imaging and post-mortem immunohistochemical findings in the evaluation of lesions induced by 6-OHDA in rats.

Bäck S, Raki M, Tuominen RK, Raasmaja A, Bergström K, Männistö PT.

EJNMMI Res. 2013 Jun 10;3(1):46. doi: 10.1186/2191-219X-3-46.

14.

Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.

Tenorio-Laranga J, Peltonen I, Keskitalo S, Duran-Torres G, Natarajan R, Männistö PT, Nurmi A, Vartiainen N, Airas L, Elovaara I, García-Horsman JA.

Biochem Pharmacol. 2013 Jun 15;85(12):1783-94. doi: 10.1016/j.bcp.2013.04.018. Epub 2013 Apr 30.

PMID:
23643808
15.

Catechol-O-methyltransferase (COMT) protein expression and activity after dopaminergic and noradrenergic lesions of the rat brain.

Schendzielorz N, Oinas JP, Myöhänen TT, Reenilä I, Raasmaja A, Männistö PT.

PLoS One. 2013 Apr 16;8(4):e61392. doi: 10.1371/journal.pone.0061392. Print 2013.

16.

Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.

Hannula MJ, Myöhänen TT, Tenorio-Laranga J, Männistö PT, Garcia-Horsman JA.

Neuroscience. 2013 Jul 9;242:140-50. doi: 10.1016/j.neuroscience.2013.03.049. Epub 2013 Apr 2. Erratum in: Neuroscience. 2013 Sep 17;248:344.

PMID:
23562579
17.

Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease.

Bäck S, Peränen J, Galli E, Pulkkila P, Lonka-Nevalaita L, Tamminen T, Voutilainen MH, Raasmaja A, Saarma M, Männistö PT, Tuominen RK.

Brain Behav. 2013 Mar;3(2):75-88. doi: 10.1002/brb3.117. Epub 2013 Jan 14.

18.

Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.

Piltonen M, Savolainen M, Patrikainen S, Baekelandt V, Myöhänen TT, Männistö PT.

Neuroscience. 2013 Feb 12;231:157-68. doi: 10.1016/j.neuroscience.2012.11.045. Epub 2012 Dec 4.

PMID:
23219665
19.

Advanced brain dopamine transporter imaging in mice using small-animal SPECT/CT.

Pitkonen M, Hippeläinen E, Raki M, Andressoo JO, Urtti A, Männistö PT, Savolainen S, Saarma M, Bergström K.

EJNMMI Res. 2012 Sep 29;2(1):55. doi: 10.1186/2191-219X-2-55.

20.

Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.

Rauhavirta T, Oittinen M, Kivistö R, Männistö PT, Garcia-Horsman JA, Wang Z, Griffin M, Mäki M, Kaukinen K, Lindfors K.

J Clin Immunol. 2013 Jan;33(1):134-42. doi: 10.1007/s10875-012-9745-5. Epub 2012 Aug 10.

PMID:
22878839
21.

Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.

Myöhänen TT, Pyykkö E, Männistö PT, Carpen O.

J Histochem Cytochem. 2012 Sep;60(9):706-15. doi: 10.1369/0022155412453051. Epub 2012 Jun 26.

22.

Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

Peltonen I, Myöhänen TT, Männistö PT.

Neurochem Res. 2012 Sep;37(9):2033-41. doi: 10.1007/s11064-012-0825-y. Epub 2012 Jun 23.

PMID:
22729983
23.

Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis.

Tammimäki A, Männistö PT.

Pharmacogenet Genomics. 2012 Sep;22(9):673-91. doi: 10.1097/FPC.0b013e3283560c46. Review.

PMID:
22722321
24.

Strong preferences of dopamine and l-dopa towards lipid head group: importance of lipid composition and implication for neurotransmitter metabolism.

Orłowski A, Grzybek M, Bunker A, Pasenkiewicz-Gierula M, Vattulainen I, Männistö PT, Róg T.

J Neurochem. 2012 Aug;122(4):681-90. doi: 10.1111/j.1471-4159.2012.07813.x. Epub 2012 Jun 27.

25.

Four day inhibition of prolyl oligopeptidase causes significant changes in the peptidome of rat brain, liver and kidney.

Tenorio-Laranga J, Männistö PT, Storvik M, Van der Veken P, García-Horsman JA.

Biochimie. 2012 Sep;94(9):1849-59. doi: 10.1016/j.biochi.2012.04.005. Epub 2012 Apr 21.

PMID:
22546504
26.

Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase.

Kaszuba K, Róg T, Danne R, Canning P, Fülöp V, Juhász T, Szeltner Z, St Pierre JF, García-Horsman A, Männistö PT, Karttunen M, Hokkanen J, Bunker A.

Biochimie. 2012 Jun;94(6):1398-411. doi: 10.1016/j.biochi.2012.03.012. Epub 2012 Mar 30.

PMID:
22484394
27.

A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Myöhänen TT, Hannula MJ, Van Elzen R, Gerard M, Van Der Veken P, García-Horsman JA, Baekelandt V, Männistö PT, Lambeir AM.

Br J Pharmacol. 2012 Jun;166(3):1097-113. doi: 10.1111/j.1476-5381.2012.01846.x.

28.

Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent programmed cell death.

Ossola B, Lantto TA, Puttonen KA, Tuominen RK, Raasmaja A, Männistö PT.

J Neurosci Res. 2012 Mar;90(3):682-90. doi: 10.1002/jnr.22791. Epub 2011 Nov 23.

PMID:
22108958
29.

Complex estrogenic regulation of catechol-O-methyltransferase (COMT) in rats.

Schendzielorz N, Rysa A, Reenila I, Raasmaja A, Mannisto PT.

J Physiol Pharmacol. 2011 Aug;62(4):483-90.

30.

A transient inhibition and permanent lack of catechol-O-methyltransferase have minor effects on feeding pattern of female rodents.

Schendzielorz N, Männistö PT, Karayiorgou M, Gogos JA, Raasmaja A.

Basic Clin Pharmacol Toxicol. 2012 Apr;110(4):307-13. doi: 10.1111/j.1742-7843.2011.00783.x. Epub 2011 Sep 28.

31.

Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.

Kääriäinen TM, Käenmäki M, Forsberg MM, Oinas N, Tammimäki A, Männistö PT.

Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):162-70. doi: 10.1111/j.1742-7843.2011.00782.x. Epub 2011 Sep 13.

32.

Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo.

Piltonen M, Planken A, Leskelä O, Myöhänen TT, Hänninen AL, Auvinen P, Alitalo K, Andressoo JO, Saarma M, Männistö PT.

Neuroscience. 2011 Sep 29;192:550-63. doi: 10.1016/j.neuroscience.2011.06.084. Epub 2011 Jul 14.

PMID:
21767614
33.

Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected].

Ossola B, Schendzielorz N, Chen SH, Bird GS, Tuominen RK, Männistö PT, Hong JS.

Neuropharmacology. 2011 Sep;61(4):574-82. doi: 10.1016/j.neuropharm.2011.04.030. Epub 2011 May 11. Erratum in: Neuropharmacology. 2012 Feb;62(2):1162.

34.

Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A.

Rauhavirta T, Qiao SW, Jiang Z, Myrsky E, Loponen J, Korponay-Szabó IR, Salovaara H, Garcia-Horsman JA, Venäläinen J, Männistö PT, Collighan R, Mongeot A, Griffin M, Mäki M, Kaukinen K, Lindfors K.

Clin Exp Immunol. 2011 Apr;164(1):127-36. doi: 10.1111/j.1365-2249.2010.04317.x. Epub 2011 Jan 14.

35.

Association of prolyl oligopeptidase with conventional neurotransmitters in the brain.

Peltonen I, Myöhänen TT, Männistö PT.

CNS Neurol Disord Drug Targets. 2011 May;10(3):311-8. Review.

PMID:
21222629
36.

Hunting for peptide substrates of prolyl oligopeptidase: classical versus non-classical bioactive peptides.

Tenorio-Laranga J, Männistö PT, García-Horsman JA.

CNS Neurol Disord Drug Targets. 2011 May;10(3):319-26. Review.

PMID:
21222622
37.

Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats.

Kambur O, Männistö PT, Pusa AM, Käenmäki M, Kalso EA, Kontinen VK.

Eur J Pain. 2011 Aug;15(7):732-40. doi: 10.1016/j.ejpain.2010.12.001. Epub 2011 Jan 8.

PMID:
21216640
38.

Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.

Voutilainen MH, Bäck S, Peränen J, Lindholm P, Raasmaja A, Männistö PT, Saarma M, Tuominen RK.

Exp Neurol. 2011 Mar;228(1):99-108. doi: 10.1016/j.expneurol.2010.12.013. Epub 2010 Dec 24.

PMID:
21185834
39.

Sequential expression, activity and nuclear localization of prolyl oligopeptidase protein in the developing rat brain.

Hannula MJ, Männistö PT, Myöhänen TT.

Dev Neurosci. 2011;33(1):38-47. doi: 10.1159/000322082. Epub 2010 Dec 14.

PMID:
21160163
40.

Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Myöhänen TT, Tenorio-Laranga J, Jokinen B, Vázquez-Sánchez R, Moreno-Baylach MJ, García-Horsman JA, Männistö PT.

Br J Pharmacol. 2011 Aug;163(8):1666-78. doi: 10.1111/j.1476-5381.2010.01146.x.

41.

Effect of genetic modifications in the synaptic dopamine clearance systems on addiction-like behaviour in mice.

Tammimäki A, Männistö PT.

Basic Clin Pharmacol Toxicol. 2011 Jan;108(1):2-8. doi: 10.1111/j.1742-7843.2010.00647.x. Epub 2010 Nov 30. Review.

42.

Catechol-O-methyltransferase and pain.

Kambur O, Männistö PT.

Int Rev Neurobiol. 2010;95:227-79. doi: 10.1016/B978-0-12-381326-8.00010-7. Review.

PMID:
21095465
43.

Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors.

Nissinen E, Männistö PT.

Int Rev Neurobiol. 2010;95:73-118. doi: 10.1016/B978-0-12-381326-8.00005-3. Review.

PMID:
21095460
44.

Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture?

Myöhänen TT, Männistö PT.

Int Rev Neurobiol. 2010;95:29-47. doi: 10.1016/B978-0-12-381326-8.00003-X. Review.

PMID:
21095458
45.

Are genetic variants of COMT associated with addiction?

Tammimäki AE, Männistö PT.

Pharmacogenet Genomics. 2010 Dec;20(12):717-41. doi: 10.1097/FPC.0b013e328340bdf2. Review.

PMID:
20975619
46.

Effects of diverse psychopharmacological substances on the activity of brain prolyl oligopeptidase.

Peltonen I, Männistö PT.

Basic Clin Pharmacol Toxicol. 2011 Jan;108(1):46-54. doi: 10.1111/j.1742-7843.2010.00626.x. Epub 2010 Sep 6.

47.

Inhibitors of catechol-O-methyltransferase sensitize mice to pain.

Kambur O, Talka R, Ansah OB, Kontinen VK, Pertovaara A, Kalso E, Männistö PT.

Br J Pharmacol. 2010 Dec;161(7):1553-65. doi: 10.1111/j.1476-5381.2010.00999.x.

48.

Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice.

Käenmäki M, Tammimäki A, Myöhänen T, Pakarinen K, Amberg C, Karayiorgou M, Gogos JA, Männistö PT.

J Neurochem. 2010 Sep;114(6):1745-55. doi: 10.1111/j.1471-4159.2010.06889.x. Epub 2010 Aug 19.

49.

Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice.

Tammimäki A, Käenmäki M, Kambur O, Kulesskaya N, Keisala T, Karvonen E, García-Horsman JA, Rauvala H, Männistö PT.

Psychopharmacology (Berl). 2010 Sep;211(4):389-401. doi: 10.1007/s00213-010-1944-2. Epub 2010 Jul 9.

PMID:
20617305
50.

Degradation of coeliac disease-inducing rye secalin by germinating cereal enzymes: diminishing toxic effects in intestinal epithelial cells.

Stenman SM, Lindfors K, Venäläinen JI, Hautala A, Männistö PT, Garcia-Horsman JA, Kaukovirta-Norja A, Auriola S, Mauriala T, Mäki M, Kaukinen K.

Clin Exp Immunol. 2010 Aug;161(2):242-9. doi: 10.1111/j.1365-2249.2010.04119.x. Epub 2010 Jun 15.

Supplemental Content

Loading ...
Support Center